Lindus

What Lindus does

Short:

Name

Lindus

Legal name

Lindus Health Limited

Website

https://lindushealth.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

101–250 employees

Short description

Lindus Health is a London-headquartered, Boston-based next-generation Contract Research Organization that delivers end-to-end clinical trials for biotech, pharmaceutical, medical device, diagnostics, and consumer health sponsors via its proprietary Citrus eClinical platform and AI-powered patient recruitment under performance-based milestone pricing.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) Services

NAICS

Other Scientific and Technical Consulting Services (54169)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical CROs (Phase I–IV) (HLAGAAAA)

akta.pro secondary industries

Patient Recruitment, Site Feasibility & Trial Enablement CROs (HLAGAAAI), Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL), Medical Writing & Regulatory Submission Support CROs (HLAGAAAG)

Keywords

• Clinical trial services
• Contract research organization
• EClinical platform software
• AI patient recruitment
• Medical device clinical trials

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Trial Services (CRO): Lindus Health operates as a next-generation Contract Research Organization (CRO) providing end-to-end clinical trial execution services. They offer milestone-based contracts structured around operational performance with financial incentives aligned with sponsor outcomes. The performance-based commercial model includes fixed-price quotes per study with milestone-based payments.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

Lindus Health is a next-generation Contract Research Organization (CRO) that runs end-to-end clinical trials for life sciences sponsors, executed through its proprietary AI-assisted Citrus eClinical platform. It sells fixed-price, milestone-based CRO engagements covering study design, regulatory, recruitment, monitoring, data management, and statistical analysis across therapeutic areas including cardiometabolic, respiratory, psychiatry, dermatology, women's health, diagnostics, medical device, consumer health, and ophthalmology.

Product overview

Lindus Health is a next-generation Contract Research Organization (CRO) operating as an 'anti-CRO' model with a technology-driven, integrated approach to clinical trial execution. The company offers an end-to-end clinical trial platform built around its proprietary Citrus eClinical System, which integrates electronic data capture (EDC), clinical trial management (CTMS), eConsent, patient scheduling, and randomization capabilities. The platform is complemented by specialized therapeutic area service offerings covering Cardiometabolic, Respiratory, Psychiatry, Women's Health, Dermatology, Diagnostics, Infectious Disease, Consumer Health, and Ophthalmology clinical trials. Lindus differentiates itself through AI-powered patient recruitment leveraging over 40 million electronic health records, a performance-based commercial model with milestone pricing, and vertically integrated site services including virtual and hybrid site capabilities.

Differentiator

Problem solved

Functional benefit

Brands

• Citrus: Proprietary eClinical trial management platform integrating CTMS, EDC, eConsent, patient scheduling, and IRT/randomization.

Products and services

• Citrus eClinical Platform Proprietary AI-assisted trial operating system integrating electronic data capture (EDC), clinical trial management system (CTMS), eConsent, patient scheduling, randomization (IRT), and ePRO. Powers end-to-end clinical trial execution from protocol design through database lock for sponsor customers.
• All-in-One Medical Device CRO Comprehensive contract research organization solution for medical device clinical trials covering Class I/II devices, diagnostics, regulatory pathways (510(k), De Novo, CE marking), with integrated recruitment, site management, and the Citrus platform.
• Cardiometabolic CRO Services Specialized clinical trial services for cardiometabolic conditions including diabetes, obesity, NASH, and hypertension, leveraging the Citrus platform and access to over 40 million EHRs for patient identification.
• Respiratory CRO Services Specialized clinical trial services for respiratory conditions including asthma and COPD, utilizing hybrid and virtual site models and digital health integrations for endpoints such as inhaler technique and adherence monitoring.
• Psychiatry CRO Services Specialized clinical trial services for CNS, neurology, and psychiatric conditions including major depressive disorder, anxiety, and insomnia, leveraging decentralized trial models.
• Women's Health CRO Services Specialized clinical trial services for women's health including menopause, fertility, and female-specific conditions, with digital therapeutic capabilities and hybrid/remote trial designs.
• Dermatology CRO Services Specialized clinical trial services for dermatological conditions including acne, eczema, atopic dermatitis, and skin cancers, covering both prescription and OTC products with photo-based assessment endpoints.
• Diagnostics CRO Services Specialized clinical trial services for diagnostic products supporting regulatory submissions and evidence generation for diagnostic innovations, including companion diagnostics and laboratory-developed tests.
• Consumer Health CRO All-in-one CRO solution for consumer health companies seeking clinical validation for wellness products including supplements, digital health interventions, and OTC medications, with diverse enrollment.
• Ophthalmology CRO Services Specialized clinical trial services for ophthalmology indications including myopia, macular degeneration, diabetic retinopathy, and dry eye, handling large imaging data volumes and long-term participant follow-up.

Quantifiable outcome

• 82% of trials completed enrollment on or ahead of proposed timeline vs 20% industry average
• +5 more outcomes

Named customers19 records

Segments10 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature5 records

Partnerships

17 partnerships are on record, tiered core and supporting.

• Nexalin TechnologycoreStrategic or Co-development Partner · 24 February 2026Clinical trial collaboration for HALO Clarity insomnia treatment device. 150+ participant pivotal trial designed to support FDA De Novo Classification Request. Lindus providing full-scope trial execution from protocol finalization through database lock.
• Quotient SciencescoreStrategic or Co-development Partner · 11 December 2025Strategic partnership to streamline drug trials from first-in-human to pivotal trials, providing a continuous development pathway. Collaboration leverages Quotient's expertise in phase 1 and Lindus' patient recruitment and 40+ million EHR access for phase 2 trials. Aims to reduce inefficiencies and delays by eliminating need for sponsors to separately source multiple CROs, involving over 70 Phase I studies annually across US and UK.
• YendousupportingTechnology or Integration · 16 October 2025Partnership leveraging Yendou's AI platform to centralize data and automate workflows for site engagement and clinical trial feasibility. Led to significant efficiencies including more qualified sites and increased data points, expanding trial reach and improving relationships with clinical sites.
• Frieda HealthcoreStrategic or Co-development Partner · 17 September 2025Collaboration for clinical trial evaluating Frieda Menova app, a digital therapeutic using CBT for menopause symptoms. Lindus provided end-to-end oversight covering regulatory submissions, participant recruitment, monitoring, data management, and statistical analysis. First clinical trial to evaluate a digital therapeutic utilizing CBT for menopause treatment.
• University of OxfordcoreStrategic or Co-development Partner · 3 April 2025ARIA-funded collaboration to develop safe and reliable AI for clinical trial design. Project aims to reduce trial setup times, lower costs, increase accuracy, and improve trust in AI tools within healthcare sector.
• Tiefenbacher GroupcoreStrategic or Co-development Partner · 6 March 2025Clinical trial partnership to advance ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome) research and treatment. Combines Tiefenbacher's pharmaceutical expertise with Lindus' end-to-end trial execution capabilities.
• Sooma MedicalcoreStrategic or Co-development Partner · 1 March 2025Partnership for pivotal phase 3 clinical trial testing Sooma's wearable tDCS cap (Sooma 2GEN) as home-based treatment for major depressive disorder. Lindus provides full-scope trial execution from protocol finalization through database lock.
• Dr. Paul Billings (Scientific Advisory Board)supportingOthers · 8 January 2025Appointment of Dr. Paul Billings, diagnostic and genomic medicine pioneer with over 40 years industry experience, to Scientific Advisory Board. Previously served as Chairman and CEO of Biological Dynamics and CMO of Natera. Will help shape strategy for diagnostic clinical trials.
• Aptar Digital HealthsupportingStrategic or Co-development Partner · 5 September 2024Collaboration with Guy's and St Thomas' NHS Foundation Trust for asthma clinical study evaluating Aptar's Respiratory Disease Management Platform. Lindus executing the 118-participant, 6-month study with clinical data evaluation including asthma control symptoms and medication adherence.
• Woebot HealthcoreStrategic or Co-development Partner · 22 August 2024Completion of two clinical trials for Woebot's digital mental health support tools for depression and anxiety. Lindus provided end-to-end study support including virtual site capabilities, Citrus platform integration with online pre-screener and eConsent. Both trials completed enrollment in under four weeks.
• PILA PHARMAcoreStrategic or Co-development Partner · 24 July 2024Agreement for Phase 2a clinical trial (PP-CT03) to assess tolerability, safety, and efficacy of XEN-D0501 in patients with type II diabetes and obesity. Lindus assisting with regulatory submissions and providing risk-shared, fixed-price, milestone-based payment model.
• AktiiacoreStrategic or Co-development Partner · 9 July 2024Launch of 7,500-participant, 12-week observational trial for Aktiia's optical blood pressure monitoring device in hypertensive individuals. Lindus providing end-to-end study management with virtual site and digital marketing capabilities.
• TassosupportingTechnology or Integration · 4 June 2024Adoption of Tasso's virtually painless remote blood collection technology to reduce patient burden in clinical trials. Enables participants to collect blood samples at home without mobile phlebotomist, improving recruitment, retention, and reducing dropout rates. Tasso technology preferred by 9 out of 10 participants over fingerstick or phlebotomy.
• Acinonyx BiosupportingStrategic or Co-development Partner · 16 May 2024Cosmetics clinical trial evaluating topical cream ACX as alternative to benzoyl peroxide for inflammatory acne. Decentralized trial model with 6-week participant treatment period and photo-based medical assessment.
• MyotacoreStrategic or Co-development Partner · 16 May 202424-week study published in British Journal of Nutrition showing prebiotic fibre supplement significantly reduces Type 2 diabetes risk. Lindus designed innovative trial with EHR-based participant identification and achieved 83% daily ePRO adherence.
• Dr. Tim Garnett (Advisory Board)supportingOthers · 8 May 2024Appointment of Dr. Tim Garnett, former Chief Medical Officer of Eli Lilly, to Advisory Board. Adds expertise in pharmaceutical clinical development and regulatory strategy.
• CLEO DiagnosticssupportingStrategic or Co-development Partner · 11 April 2024U.S. ovarian cancer clinical trial management for CLEO Diagnostics detection product. Lindus providing end-to-end clinical operations for pivotal trial supporting FDA submission.

Scale indicators10 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Medpace: Mid-size, tech-forward full-service CRO with a reputation for operational excellence and on-time enrollment. Closest direct comp to Lindus given similar size positioning and "operating-system" approach.
• Worldwide Clinical Trials: Mid-tier, therapeutically specialized CRO focused on complex studies across cardiometabolic, oncology, CNS, and rare disease. Comparable mid-scale, TA-focused operating model targeting similar biotech and pharma customers.
• Celerion: Specialized clinical CRO with strong early-phase and Phase I expertise, often partnering for Phase II+ work. Comparable in therapeutic specialization and Phase I collaboration profile to Lindus's Quotient Sciences partnership dynamic.

Broad incumbents

• IQVIA: Largest global CRO and life sciences services firm offering full-service clinical execution, real-world evidence, and technology. The dominant incumbent Lindus positions against; comparable on broad clinical services but vastly greater scale.
• ICON plc: Global CRO formed via PRA Health Sciences merger, offering end-to-end clinical development and post-approval services. Comparable full-service clinical execution across all phases and TAs to Lindus but at substantially larger scale.
• Parexel: Large global CRO providing full-service Phase I–IV clinical development, with therapeutic depth across oncology, rare disease, and CNS. Comparable breadth of clinical services and enterprise pharma customer base.
• Syneos Health: Large clinical-to-commercial CRO with decentralized and site solutions capabilities. Comparable on integrated clinical execution plus site-network operational breadth targeting biotech and large pharma.
• PPD (Thermo Fisher Scientific): Major global CRO acquired by Thermo Fisher, providing end-to-end clinical development services across all phases. Comparable full-service clinical execution model serving large pharmaceutical customers.

Emerging players

• Velocity Clinical Research: Integrated multi-therapeutic site-network plus CRO hybrid, focused on decentralized and community-based trials. Comparable emerging operational model combining site ownership with tech-enabled clinical execution for similar biotech/mid-pharma customers.
• Curebase: Decentralized clinical trial technology and operations company enabling remote and hybrid trial execution. Comparable emerging-tech CRO peer with comparable tech-forward, decentralized-trial go-to-market targeting similar biotech customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/lindustx
• YouTubeyoutube.com/@LindusHealth
• Facebookfacebook.com/LindusTherapeutics
• LinkedInlinkedin.com/company/lindushealth

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds6 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Lindus